UOC
KIN

UBS O'Connor’s Kindred Biosciences, Inc. KIN Stock Holding History

UBS O'Connor’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100,000
Closed -$1.06M – 348
2018
Q2 		$1.06M Buy
+100,000
New +$975K 0.02% 205
2014
Q4 		– Sell
-98,295
Closed -$909K – 739
2014
Q3 		$909K Buy
+98,295
New +$1.33M 0.02% 354

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

UBS O'Connor's KIN Position: Q3 2018 in Review

UBS O'Connor sold out of Kindred Biosciences, Inc. (KIN) in Q3 2018, closing a stake of 100,000 shares — an estimated $1.06M sold.

UBS O'Connor first reported a position in KIN in Q3 2014 and held it in 2 quarters. The position peaked at $1.06M in Q2 2018. 81 funds tracked by Wall St. Rank hold KIN as of Q3 2018.

  • UBS O'Connor reported no remaining Kindred Biosciences, Inc. position as of Q3 2018 after selling out during the quarter.
  • UBS O'Connor sold 100,000 Kindred Biosciences, Inc. shares in Q3 2018, an estimated $1.06M.
  • UBS O'Connor first reported a position in Kindred Biosciences, Inc. in Q3 2014 and held it in 2 quarters.
  • UBS O'Connor's Kindred Biosciences, Inc. position peaked at $1.06M in Q2 2018.
  • 81 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2018.

Based on UBS O'Connor's 13F filing for Q3 2018, filed 14 Nov 2018.